Introduction

On April 4, 2026, China's National Medical Products Administration (NMPA) issued the 103rd batch of the Reference Listed Drug (RLD) Directory for Generic Drugs, including eight new products such as Zeluxbren Sodium Injection. This update is critical for overseas API manufacturers, CDMOs, and generic drug exporters targeting the Chinese market, as it provides official reference standards for domestic generic drug companies pursuing international registrations (e.g., ANDA, EDMF). The directory also signals a clear procurement window for foreign suppliers of reference drugs or excipients.

Event Overview

The NMPA's latest RLD directory update, published on April 4, 2026, adds eight new reference drugs, with Zeluxbren Sodium Injection being a notable inclusion. This batch serves as a regulatory benchmark for generic drug development and international market entry. No additional policy changes or implementation timelines were disclosed in the announcement.

Impact on Sub-Sectors

Overseas API Manufacturers & CDMOs

The inclusion of specific APIs like Zeluxbren Sodium creates immediate demand for compliant suppliers. Companies with pre-qualified facilities should prioritize capacity allocation for Chinese orders, as the directory effectively opens a 12-18 month procurement cycle for reference drugs.

Domestic Generic Drug Developers

Chinese firms now have official reference standards for bioequivalence studies targeting ANDA/EDMF submissions. This reduces formulation development risks but requires rapid analytical method validation against the new RLDs.

Supply Chain Intermediaries

Logistics providers specializing in temperature-controlled API shipments should anticipate increased China-bound volumes, particularly for injectable products listed in this batch.

Key Action Points

Monitor Follow-Up Technical Guidelines

The NMPA typically releases detailed bioequivalence study requirements 2-3 months after RLD publication. International manufacturers should track these updates through local regulatory partners.

Prioritize Listed API Variants

Suppliers of Zeluxbren Sodium and other listed compounds should immediately verify their DMFs against China's technical requirements, as formulation differences may necessitate additional documentation.

Expedite Import Testing Preparations

Given China's strict API import testing protocols, overseas suppliers should pre-arrange sample quantities for customs testing to avoid shipment delays during the peak procurement period.

Industry Perspective

Analysis suggests this update reflects China's continued alignment with ICH Q12 guidelines, accelerating generic drug globalization. While not a policy shift, the consistent quarterly RLD updates since 2024 demonstrate systematic market access opportunities for compliant international suppliers. The inclusion of novel APIs like Zeluxbren Sodium indicates NMPA's focus on expanding therapeutic category coverage.

Conclusion

The 103rd RLD directory update operationalizes market entry pathways rather than introducing new regulations. Industry participants should view this as a predictable procurement trigger rather than a disruptive policy event. The immediate focus should be on technical compliance verification and supply chain coordination for the listed APIs.

Source

National Medical Products Administration (NMPA) official announcement, April 4, 2026. Ongoing monitoring required for subsequent technical implementation guidelines.